EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Postoperative Anti‐IgE Therapy for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Efficacy and Prognostic Factors

Xiaomei Yang iD, Menghan Ye, Minghao Pan, Jiashu Zhao iD, Yang Liu iD, Xuelan Zeng, Wendong Liu iD, Yueqi Sun iD, Yi Wei, Fenghong Chen, Rui Xu iD

International Forum of Allergy & Rhinology · 2025

DOI: 10.1002/alr.23626 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Xiaomei Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Otorhinolaryngology Hospital of the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Asthma, Nasal Polyps, Omalizumab. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Natural Science Foundation of Guangdong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Omalizumab has demonstrated efficacy in treating chronic rhinosinusitis (CRS) with nasal polyps and comorbid asthma (NPwAS) in preoperative settings. However, real‐world evidence regarding its postoperative application remains limited. This study aimed to assess the effectiveness and safety of omalizumab in managing NPwAS following endoscopic sinus surgery (ESS), and to identify predictors for treatment response.

Methods

This prospective observational study enrolled 60 NPwAS patients who underwent ESS between January 2020 and March 2023. Participants were divided into two groups: Control group (receiving standard care: nasal saline lavage and budesonide nasal spray) and Omalizumab group (receiving omalizumab in addition to standard care). Disease assessments, including total nasal symptom score (TNSS), visual analog scale (VAS) score, asthma control test (ACT), and sino‐nasal outcome test‐22 (SNOT‐22), were conducted at baseline and 6 months post‐treatment. Blood and nasal polyp tissue samples were collected to explore potential predictors. CRS disease control was categorized as controlled, partly controlled, or uncontrolled based on the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS).

Results

Thirty patients in the Omalizumab group and 28 in the Control group completed the treatment and follow‐up. At 6 months, CRS control was significantly better in the Omalizumab group compared to the Control group, with response rates of 40% and 14.3%, respectively ( p = 0.009). The Omalizumab group also demonstrated greater mean improvements from baseline in TNSS, loss of smell score, and SNOT‐22 score compared to the Control group. The treatment exhibited a favorable safety profile.

Conclusions

Omalizumab significantly improved clinical outcomes in NPwAS patients 6 months post‐surgery, underscoring its potential as an effective adjunctive therapy in the postoperative management of NPwAS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Allergic AgentsAsthmaNasal PolypsOmalizumabRhinosinusitisAdultAgedFemaleHumansMaleMiddle AgedChronic DiseaseEndoscopyPrognosisProspective StudiesTreatment OutcomeAntibodies, Anti-Idiotypic

Stichwörter der Autor:innen

CRSIgENPwASasthmaendoscopic sinus surgeryomalizumabpostoperative

Substanzen

Anti-Allergic Agentsanti-IgE antibodiesOmalizumabAntibodies, Anti-Idiotypic

Autor:innen und Institutionen

  • Department of Allergy, Otorhinolaryngology Hospital of the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Department of Otorhinolaryngology, Clifford Hospital, Guangzhou, China.
  • Department of Otolaryngology, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
  • Department of Otolaryngology, Head and Neck Surgery, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

ORCID-Profile: Xiaomei Yang, Jiashu Zhao, Yang Liu, Wendong Liu, Yueqi Sun, Rui Xu

Förderung

  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Yang, X., Ye, M., Pan, M., Zhao, J., Liu, Y., Zeng, X., Liu, W., Sun, Y., Wei, Y., Chen, F., & Xu, R. (2025). Postoperative Anti‐IgE Therapy for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Efficacy and Prognostic Factors. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23626

Vancouver

Yang X, Ye M, Pan M, Zhao J, Liu Y, Zeng X, et al. Postoperative Anti‐IgE Therapy for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Efficacy and Prognostic Factors. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23626

BibTeX
@article{Yang2025,
  author = {Yang, Xiaomei and Ye, Menghan and Pan, Minghao and Zhao, Jiashu and Liu, Yang and Zeng, Xuelan and Liu, Wendong and Sun, Yueqi and Wei, Yi and Chen, Fenghong and Xu, Rui},
  title = {Postoperative Anti‐IgE Therapy for Chronic Rhinosinusitis With Nasal Polyps and Asthma: Efficacy and Prognostic Factors},
  journal = {International Forum of Allergy & Rhinology},
  year = {2025},
  doi = {10.1002/alr.23626}
}
Kostenlos starten →